TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidanceAug 3Quarterly updateTG Therapeutics, Inc.ublituximab
TG Therapeutics registers two Phase 2 ublituximab trials, in schizophrenia and myasthenia gravisJul 2Weekly roundup, 2 itemsTG Therapeutics, Inc.ublituximab
Sign inSign in